Foley Partner Mark Waxman was quoted in an article titled “What impact will Obama administration have on human subjects research?” in the February 1, 2010 issue of IRB Advisor. Waxman discusses proposed changes to the health care industry under the Obama administration, stating that a possible change would be the lifting of the ban on federal funding of stem cell research and an increase in the number of stem cell trials. He adds that two bills to watch are the Fair Access to Clinical Trials act, which would strengthen a national data base of clinical trials information, and the Physician Payments Sunshine Act of 2008, which calls for transparency in physician relationships with pharmaceutical and device companies.
Related News
December 24, 2025
In the News
Kyle Faget on HHS Gender-Affirming Care Declaration – Impact is 'Enormous'
Foley & Lardner LLP partner Kyle Faget commented on the recent Department of Health and Human Services declaration rejecting gender-affirming care in the STAT News article, “Nineteen states, D.C. sue HHS over gender-affirming care crackdown."
December 22, 2025
In the News
Monica Call in Law.com Leadership Spotlight – 'I see my role as both coach and advocate'
Foley & Lardner LLP partner Monica Call reflects on leadership, mentorship, and strategy in Law.com's "How I Made It Office Managing Partner" series.
December 18, 2025
In the News
Kyle Faget Weighs in on HHS Proposed Rule Limiting Gender-Affirming Care
Foley & Lardner LLP partner Kyle Faget commented on a recent proposal from the U.S. Department of Health and Human Services in the Law360 article, “HHS Proposes Hospital Ban On Gender Care For Minors.”